Abstract

TO CORRELATE THE CLINICAL FEATURES, HISTOPATHOLOGY AND EPIDEMIOLOGY WITH EGFR/ALK MUTATION AND TREATMENT RESPONSE IN NSCLC

*Ms. Vidhi H. Prajapati, Dr. Jayant B. Dave, Dr.Chirag J. Desai

ABSTRACT

Aim &Objective: To correlate the clinical features, histopathology and epidemiology with EGFR/ALK mutation and treatment response in NSCLC. Settings And Design: Single centric, retrospective & prospective study. Material &Method: Prospective and retrospective, single centric 6 months study in which 25 NSCLC patients were screened and subjected to EGFR/ALK mutation testing. The treatment with TKIs was generally decided based on EGFR/ALK mutation results and the standard practice at the clinic.During study, demographic details, clinical features and histopathological data of the patients were collected. Results: Incidence of NSCLC was significantly higher in male (64%) than female (36%). The incidence of EGFR mutation +Veand ALK mutation +Ve was 28% and was 8% respectively. Out of that 24% male & 4% female were EGFR mutation +Ve while 0% male & 8% female were ALK mutation +Ve. The proportion of non-smokers was higher than smokers(68% vs 32%) in the patients studied. The EGFR and ALK mutation did not differ significantly between high and low risk groups viz smokers-nonsmokers, tobacco consumers-non consumers. From 25 patients, 24(96%) had adenocarcinoma & only 1 had squamous cell carcinoma. The clinical benefit rate was 100% with TKI as well as chemotherapy. The progression free survival (PFS) appeared longer with chemotherapy than EGFR TKI (7.5 vs 4 months). The response of ALK TKI was measured by percentage response rate (100%) & PFS(5 months) in ALK +ve patients. Conclusion: There was no significant difference between different risk factors and EGFR/ALK occurrence. The response rate was good with TKI as well as chemotherapy as measured by %RR & PFS. The response of ALK TKI was quite good.

Keywords: NSCLC, EGFR/ALK mutation, Treatment response, EGFR/ALK TKIs